Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 20INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Small Cell Lung Carcinoma 22Carcinoma, Hepatocellular 17Neoplasms 15Lung Neoplasms 14Biliary Tract Neoplasms 12Neoplasm Metastasis 11Breast Neoplasms 11Recurrence 10Squamous Cell Carcinoma of Head and Neck 9Melanoma 9Carcinoma 9Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Liver Neoplasms 7Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Lymphoma 5Uterine Cervical Neoplasms 4Neoplasms by Site 4Multiple Myeloma 4Lymphoma, Follicular 4Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × durvalumab × Clear all
NCT03611556 2023-10-03

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

MedImmune LLC

Phase 1/2 Completed
213 enrolled 42 charts
Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT02734160 2019-08-05

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1 Completed
37 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Pharmacyclics LLC.

Phase 1/2 Completed
124 enrolled 17 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡